EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische Studie

Comparison of bone mineral density changes between denosumab and bisphosphonates in tenofovir-exposed chronic hepatitis B patients with osteoporosis

Yunmi Ko, Byeong Geun Song, Hyunjae Shin, Youngsu Park, Jeayeon Park, Min Kyung Park, Yun Bin Lee, Su Jong Yu, Dong Hyun Sinn, Yoon Jun Kim, Jung-Hwan Yoon, Seung Shin Park und 2 weitere

Osteoporosis International · 2025

DOI: 10.1007/s00198-025-07602-1 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Osteoporosis International, 2025. Verfasst von Yunmi Ko und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Antiviral Agents, Bone Density Conservation Agents, Denosumab, Diphosphonates. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study compared denosumab and bisphosphonates for osteoporosis in tenofovir-exposed chronic hepatitis B patients. Both denosumab and bisphosphonates increased bone mineral density (BMD) at year 1. However, denosumab resulted in a greater BMD improvement and a more pronounced reduction in procollagen type 1 N-terminal peptide (P1NP) compared to bisphosphonate. These findings suggest that while both drugs have beneficial effects, denosumab may be the more effective therapeutic option in this population. BACKGROUND: Tenofovir disoproxil fumarate (TDF), a first-line antiviral for chronic hepatitis B (CHB), is a risk factor for osteoporosis. This study aimed to compare the effectiveness of denosumab and bisphosphonates for osteoporosis in TDF-exposed CHB patients. METHODS: CHB patients who were treated with either denosumab or bisphosphonates for newly diagnosed osteoporosis during > 1 year of TDF treatment between 2010 and June 2024 were included from two tertiary centers in Korea. The primary outcome was bone mineral density (BMD) change at year 1 in the lumbar spine (LS) and femoral neck (FN). Secondary outcomes included changes in two bone turnover markers, procollagen type 1 N-terminal propeptide (P1NP) and C-telopeptide of type 1 collagen (CTX). RESULTS: A total of 155 patients were included: 79 received denosumab and 76 received bisphosphonates. The median time from TDF initiation to osteoporosis diagnosis was 4.8 years. After balancing baseline characteristics using propensity score matching, the denosumab group showed a significant increase in BMD at the LS and FN (denosumab vs. bisphosphonates: LS, 11.7% vs. 6.4%, P = 0.001; FN, 4.9% vs. 1.7%, P = 0.008) at year 1. The denosumab group had a greater reduction in P1NP levels at 6 months (-72.7% vs. -63.8%, P = 0.001), with no significant difference in CTX changes (-70.8% vs. -71.4%, P = 0.74) compared to the bisphosphonates group. The inverse probability of treatment weighting analyses reproduced a similar trend. CONCLUSIONS: In TDF-exposed CHB patients with osteoporosis, denosumab outperformed bisphosphonates in the LS and FN BMD at year 1. The reduction in P1NP level was also more prominent in the denosumab group.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsBone Density Conservation AgentsDenosumabDiphosphonatesHepatitis B, ChronicOsteoporosisTenofovirAdultAgedFemaleHumansMaleMiddle AgedBone DensityFemur NeckLumbar VertebraeRetrospective StudiesPeptide FragmentsProcollagen

Stichwörter der Autor:innen

Antiresorptive agentsChronic hepatitis BOsteoporosisTenofovir disoproxil fumarate

Substanzen

Antiviral AgentsBone Density Conservation AgentsDenosumabDiphosphonatesprocollagen Type I N-terminal peptideTenofovirPeptide FragmentsProcollagen

Autor:innen und Institutionen

  • Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.
  • Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. parkseungsin@gmail.com.
  • Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea. mhhur@snu.ac.kr.
  • Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea. pindra@empal.com.

Zitieren

APA

Ko, Y., Song, B. G., Shin, H., Park, Y., Park, J., Park, M. K., Lee, Y. B., Yu, S. J., Sinn, D. H., Kim, Y. J., Yoon, J. H., Park, S. S., Hur, M. H., & Lee, J. H. (2025). Comparison of bone mineral density changes between denosumab and bisphosphonates in tenofovir-exposed chronic hepatitis B patients with osteoporosis. Osteoporosis International. https://doi.org/10.1007/s00198-025-07602-1

Vancouver

Ko Y, Song BG, Shin H, Park Y, Park J, Park MK, et al. Comparison of bone mineral density changes between denosumab and bisphosphonates in tenofovir-exposed chronic hepatitis B patients with osteoporosis. Osteoporosis International. 2025. doi:10.1007/s00198-025-07602-1

BibTeX
@article{Ko2025,
  author = {Ko, Yunmi and Song, Byeong Geun and Shin, Hyunjae and Park, Youngsu and Park, Jeayeon and Park, Min Kyung and Lee, Yun Bin and Yu, Su Jong and Sinn, Dong Hyun and Kim, Yoon Jun and Yoon, Jung-Hwan and Park, Seung Shin and Hur, Moon Haeng and Lee, Jeong-Hoon},
  title = {Comparison of bone mineral density changes between denosumab and bisphosphonates in tenofovir-exposed chronic hepatitis B patients with osteoporosis},
  journal = {Osteoporosis International},
  year = {2025},
  doi = {10.1007/s00198-025-07602-1}
}
Kostenlos starten →